



TO: Our Valued Clients and Brokers
FROM: Health Plans, Inc.
DATE: December 29, 2022
RE: Compliance *eBlast*: Update On RxDC Reporting

Health Plans, Inc. (HPI) is issuing this Compliance *eBlast* to notify you of HPI's successful filing for the Prescription Drug Data Collection (RxDC) Reporting for 12/27/2022 pursuant to the Consolidated Appropriations Act of 2021. Additionally, this *eBlast* contains an attached FAQ that was issued on 12/23/2022 by the Departments of Labor, Health and Human Services, and the Treasury detailing an extension to 1/31/2023 for plans to file their part of the RxDC Report and informing that there will be no penalties for good faith compliance for the 2022 submission.

HPI's basic approach for the 2022 RxDC Report has not changed since being detailed in the 9/9/2022 Regulatory Affairs and Action Update found [here](#) – HPI submitted D2 Medical Data for any months during 2020 and 2021 that plans were active with HPI along with a P2 Plan List and a Narrative Response. Additional details will be issued in a more comprehensive Compliance Alert in January.

Please do not reply to this email. Please contact the HPI Account Service Team directly if you have questions.

Regards,

Andrew H. A. Meggison

Director, Regulatory Affairs

HealthPlansInc.com

1500 West Park Drive, Suite 330

Westborough, MA 01581

The information in this Compliance *eBlast* is intended to provide a summary of our understanding of recent regulatory developments which may affect our clients' plans. It should not be construed as specific legal advice or legal opinion.